Abstract

Tumor necrosis factor-alpha antagonist and demielynating diseases

Anti-TNF treatment associated disorders have emerged as a new class of drug- related demielynating neurological disease. Neurological deficits that develop during treatment with TNF-alfa antagonists are relatively rare (the prevalence of demielynating disease, as reported in randomized controlled trials and postmarketing studies, has been estimated to range from 0,02-0,2%) but important potential complications of these drugs. Most of the patients described in the literature had no personal or family history of Multiple Sclerosis. These disorders include, among others, multiple sclerosis, optic neuritis, and various forms of peripheral demyelinating neuropathy. Short-term follow-up indicates relatively good outcomes, sometimes after just treatment discontinuation, although corticosteroids or intravenous immunoglobulin may be necessary to reverse and stabilize these disorders. Definitive cessation of the biological therapy should be discussed on a case-by-case basis.


Author(s):

J Balsalobre Aznar, J Porta-Etessam , J Salvatierra Ossorio, J L Rosales-Alexander



Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+
30+ Million Readerbase
Abstracted/Indexed in
  • Google Scholar
  • Open J Gate
  • Genamics JournalSeek
  • The Global Impact Factor (GIF)
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • WorldCat
  • Proquest Summons
  • Scientific Journal Impact Factor
  • Secret Search Engine Labs
  • Euro Pub

View More »

Flyer image